Group 1 - China Metallurgical Group Corporation signed new contracts worth 760.67 billion yuan from January to September, a decrease of 14.7% year-on-year, with overseas contracts increasing by 10.1% to 66.9 billion yuan [1] - Huajian Group reported new contracts of 5.47 billion yuan for the same period, down 20.59% year-on-year [1] - Xiaogoods City achieved a net profit of 3.457 billion yuan in the first three quarters, a year-on-year increase of 48.5% [1] Group 2 - Xianda Co. expects a net profit of 180 million to 205 million yuan for the first three quarters, a year-on-year increase of 2807.87% to 3211.74% [2] - Energy Guozhen's shareholder plans to increase their stake by no less than 2% of the company's shares [2] Group 3 - Bohai Automobile's major asset restructuring plan has been approved by the Beijing State-owned Assets Supervision and Administration Commission [4] Group 4 - Greatech Materials' actual controller and chairman has been placed under detention [5] Group 5 - Jibite expects a net profit of 1.032 billion to 1.223 billion yuan for the first three quarters, a year-on-year increase of 57% to 86% [6] - Xianggang Technology anticipates a net profit of 94 million to 100 million yuan for the same period, a year-on-year increase of 182% to 200% [8] Group 6 - Shaanxi Construction Group signed new contracts worth 187.979 billion yuan from January to September [9] - Shaanxi Construction's subsidiaries won two major EPC projects worth over 5 billion yuan [11] Group 7 - Zhongmu Co. received a new veterinary drug registration certificate for its inactivated vaccine against the Seneca Valley virus [13] Group 8 - Zijiang Enterprises expects a net profit of 897 million to 1.002 billion yuan for the first three quarters, a year-on-year increase of 70% to 90% [14] Group 9 - Shanghai Airport reported a 11.69% year-on-year increase in passenger throughput in September [15] Group 10 - ST Huayang applied for a credit limit of no more than 100 million yuan from Guangdong Nanyue Bank [17] Group 11 - Jinjiang Shipping expects a net profit of approximately 1.17 billion to 1.2 billion yuan for the first three quarters, a year-on-year increase of 62.72% to 66.89% [19] Group 12 - Atlantic anticipates a net profit of 135 million to 149 million yuan for the first three quarters, a year-on-year increase of 57% to 73% [21] Group 13 - Haineng Technology's subsidiary received approval for an annual production capacity of 158,000 tons of bio-aviation fuel [22] Group 14 - ZGC's subsidiary's drug listing application has been accepted by the National Medical Products Administration [23] Group 15 - Baoding Technology received a cash dividend of 78 million yuan from its wholly-owned subsidiary [24] Group 16 - Shanneng Electric's stock issuance application has been approved by the Shenzhen Stock Exchange [26] Group 17 - Jianglong Shipbuilding signed a sales contract for a 7.299 million yuan fishery enforcement vessel [29] Group 18 - Luyin Investment's controlling shareholder plans to increase its stake by 40 million to 80 million yuan [30] Group 19 - Jida Communication plans to establish an artificial intelligence joint laboratory with Jilin University [31] Group 20 - Filihua plans to raise no more than 300 million yuan for a quartz electronic yarn project [32] Group 21 - Visionox plans to invest 190 million yuan in a new materials equity investment fund [33] Group 22 - Lihesheng's semiconductor equipment project is in the preparatory stage [35] Group 23 - Pulit expects a net profit of 321 million to 351 million yuan for the first three quarters, a year-on-year increase of 53.48% to 67.82% [37] Group 24 - Linyi Intelligent Manufacturing expects a net profit of 1.89 billion to 2.12 billion yuan for the first three quarters, a year-on-year increase of 34.1% to 50.42% [38] Group 25 - Xichang Electric expects a net profit of approximately 1.24 million yuan for the first three quarters, a year-on-year increase of about 150.51% [39] Group 26 - Sanmei Co. expects a net profit of 1.524 billion to 1.646 billion yuan for the first three quarters, a year-on-year increase of 171.73% to 193.46% [40] Group 27 - Yuegui Co. expects a net profit of 420 million to 470 million yuan for the first three quarters, a year-on-year increase of 86.87% to 109.11% [42] Group 28 - Dongyue Silicon Material expects a net profit of 2.3 million to 3.3 million yuan for the first three quarters, a year-on-year decrease of about 96.27% to 97.40% [43] Group 29 - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau [45] Group 30 - Jindi Group reported a 57.12% year-on-year decrease in signed amount for September [46] Group 31 - Salt Lake Co. expects a net profit of 4.3 billion to 4.7 billion yuan for the first three quarters, a year-on-year increase of 36.89% to 49.62% [47] Group 32 - Kaifa Electric plans to raise 300 million yuan for technology upgrades and AI platform projects [50] Group 33 - Kalate plans to establish a joint venture focusing on AI high-performance computing [51] Group 34 - Three Gorges Water Conservancy reported a 5.98% year-on-year decrease in power generation for the first three quarters [52] Group 35 - Invek reported a 25.8% year-on-year increase in revenue for the first three quarters [54] Group 36 - ST Tian Sheng's subsidiary is expected to be selected for the procurement of certain pharmaceuticals [56] Group 37 - Fujilai plans to repurchase shares worth 20 million to 40 million yuan [59] Group 38 - Sun Cable's shareholder plans to reduce its stake by no more than 3% [60] Group 39 - Ji'an Medical plans to repurchase shares worth 300 million to 600 million yuan [60]

Core Viewpoint - The stock price of Bio Co., Ltd. has shown significant growth this year, with a year-to-date increase of 45.39% and a recent surge of 14.01% over the last five trading days [2] Financial Performance - As of June 30, 2025, Bio Co., Ltd. reported a revenue of 620 million yuan, reflecting a year-on-year growth of 1.28%. However, the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2] - The company has cumulatively distributed dividends of 2.219 billion yuan since its A-share listing, with 18.9 million yuan distributed over the last three years [3] Stock Market Activity - The stock price reached 9.93 yuan per share with a market capitalization of 11.04 billion yuan as of October 10, 2023. The trading volume was 204 million yuan, with a turnover rate of 1.88% [1] - Bio Co., Ltd. has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 123 million yuan on July 17, 2023 [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 3.84% to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% [2] - Major institutional shareholders include Guotai Zhenzhong Livestock Breeding ETF and Southern Zhenzhong 1000 ETF, with both increasing their holdings [3]

Company Overview - KQ Bio, established on January 11, 2001, is located in Wuhan, Hubei Province, and specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1] - The company was listed on September 22, 2020, and its main business revenue composition is 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1] Stock Performance - As of September 30, KQ Bio's stock price increased by 2.00% to 17.83 CNY per share, with a total market capitalization of 8.31 billion CNY [1] - Year-to-date, the stock price has risen by 28.63%, with a 1.54% increase over the last five trading days, a 0.34% decrease over the last 20 days, and an 11.44% increase over the last 60 days [1] Financial Performance - For the first half of 2025, KQ Bio reported a revenue of 487 million CNY, representing a year-on-year growth of 21.67%, and a net profit attributable to shareholders of 220 million CNY, which is a 44.09% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 711 million CNY, with 488 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, KQ Bio had 9,484 shareholders, an increase of 19.03% from the previous period, with an average of 49,148 circulating shares per shareholder, a decrease of 15.98% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 2.3577 million shares as a new shareholder [3]

Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

Core Viewpoint - The stock of Jinyu Biological Technology Co., Ltd. has shown a significant increase of 30.31% year-to-date, despite a recent decline of 1.11% over the past five trading days [1][2] Company Overview - Jinyu Biological Technology Co., Ltd. is located in Hohhot, Inner Mongolia, and was established on March 13, 1993, with its stock listed on January 15, 1999. The company primarily engages in the research, production, and sales of veterinary biological products [1] - The main revenue composition includes 94.42% from biopharmaceuticals, 3.18% from other income, and 2.40% from supplementary sources [1] Financial Performance - For the first half of 2025, the company reported an operating income of 620 million yuan, reflecting a year-on-year growth of 1.28%. However, the net profit attributable to shareholders decreased by 50.84% to 60.42 million yuan [2] - Cumulatively, the company has distributed 2.219 billion yuan in dividends since its A-share listing, with 189 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 54,900, with an average of 20,405 circulating shares per person, a decrease of 3.70% from the previous period [2] - The top ten circulating shareholders include notable ETFs, with the Guotai Zhongzheng Livestock Breeding ETF holding 15.95 million shares, an increase of 648,300 shares from the previous period [3]

Core Viewpoint - The stock price of Reap Bio fell by 2.00% on September 22, 2023, with a current price of 21.51 CNY per share and a market capitalization of 9.997 billion CNY [1] Group 1: Stock Performance - Reap Bio's stock has increased by 18.99% year-to-date, but has decreased by 2.14% in the last five trading days and 8.39% over the last 20 days [2] - The stock has shown a 10.76% increase over the past 60 days [2] Group 2: Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2] - The company's main business revenue composition is 77.95% from animal health and 22.05% from the pet supply chain [2] - Reap Bio is classified under the agricultural and animal health industry, with concepts including avian influenza drugs, pet economy, raw materials, synthetic biology, and investments in the New Third Board [2] Group 3: Financial Performance - For the first half of 2025, Reap Bio achieved a revenue of 1.708 billion CNY, representing a year-on-year growth of 55.37%, and a net profit attributable to the parent company of 257 million CNY, up 61.19% year-on-year [2] - Since its A-share listing, Reap Bio has distributed a total of 1.371 billion CNY in dividends, with 462 million CNY distributed over the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Reap Bio had 26,000 shareholders, with an average of 12,883 circulating shares per person [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3]

Company Overview - KQ Bio is located in Wuhan, Hubei Province, and was established on January 11, 2001. The company was listed on September 22, 2020. Its main business involves the research, production, and sales of veterinary biological products, as well as animal epidemic prevention technology services [1][2]. - The revenue composition of KQ Bio is as follows: 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - As of June 30, 2025, KQ Bio achieved an operating income of 487 million yuan, representing a year-on-year growth of 21.67%. The net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 44.09% [2]. - Since its A-share listing, KQ Bio has distributed a total of 711 million yuan in dividends, with 488 million yuan distributed over the past three years [2]. Stock Performance - On September 16, KQ Bio's stock price decreased by 2.05%, trading at 18.20 yuan per share, with a total market capitalization of 8.484 billion yuan [1]. - Year-to-date, KQ Bio's stock price has increased by 31.29%. Over the past five trading days, it has decreased by 0.76%, while it has increased by 3.59% over the past 20 days and by 17.42% over the past 60 days [1]. Shareholder Information - As of June 30, 2025, KQ Bio had 9,484 shareholders, an increase of 19.03% from the previous period. The average number of circulating shares per shareholder was 49,148, which decreased by 15.98% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the newest shareholder, holding 2.3577 million shares [2]. Market Position - KQ Bio is classified under the Shenwan industry category of Agriculture, Forestry, Animal Husbandry, and Fishery - Animal Health II - Animal Health III. The company is associated with several concept sectors, including margin trading, synthetic biology, vaccines, small-cap stocks, and in vitro diagnostics [1].

Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, sales, and related technology transfer of veterinary biological products, chemical drugs, and traditional veterinary medicine [1][2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Stock Performance - As of September 16, Pulaike's stock price decreased by 2.07% to 14.21 yuan per share, with a total market capitalization of 4.918 billion yuan. The stock has seen a year-to-date increase of 14.92%, but has declined by 1.93% over the last five trading days and 6.76% over the last twenty days [1]. - The stock's trading volume on September 16 was 32.122 million yuan, with a turnover rate of 0.65% [1]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average circulating shares per person decreased by 4.09% to 19,234 shares [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF (159865) ranked as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares from the previous period [3]. Business Segments - Pulaike's main business revenue composition includes: poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), pet vaccines (1.38%), and other income sources [1].

Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]

Company Overview - Shenlian Bio is located in Minhang District, Shanghai, established on June 28, 2001, and listed on October 28, 2019. The company specializes in the research, production, and sales of veterinary biological products, with 99.24% of its main business revenue coming from this sector [1][2]. Financial Performance - As of June 30, Shenlian Bio reported a revenue of 122 million yuan for the first half of 2025, a year-on-year decrease of 3.68%. The net profit attributable to the parent company was -12.87 million yuan, showing a year-on-year increase of 62.71% [2]. - The company has cumulatively distributed 158 million yuan in dividends since its A-share listing, with 47.22 million yuan distributed over the past three years [3]. Stock Performance - On September 12, Shenlian Bio's stock price increased by 2.07%, reaching 11.85 yuan per share, with a trading volume of 76.35 million yuan and a turnover rate of 1.61%. The total market capitalization is 4.866 billion yuan [1]. - Year-to-date, the stock price has risen by 116.64%, with a 0.77% increase over the last five trading days, a 10.85% increase over the last 20 days, and a 106.45% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on August 19, where it recorded a net purchase of 16.15 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Shenlian Bio was 9,466, an increase of 6.46% from the previous period. The average circulating shares per person decreased by 6.06% to 43,380 shares [2]. Industry Classification - Shenlian Bio belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the animal health industry, and is associated with concepts such as small-cap stocks, pet economy, margin trading, vaccines, and biomedicine [2].